Novel organic arsenic molecule darinaparsin: Development of IV and oral forms

Izidore S. Lossos(University of Miami), Wilson H. Miller(Jewish General Hospital), Philip Komarnitsky(Rodin Therapeutics (United States)), Michael Craig(Edith Cowan University), Paul Conkling(Virginia Oncology Associates), Carlos Becerra(Texas Oncology), Betty L. Hamilton(Baylor University Medical Center), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Ralph V. Boccia(Center for Cancer and Blood Disorders), J. Lewis(Baylor University Medical Center)
Journal of Clinical Oncology
May 20, 2009
Cited by 5


Related Papers